Sanofi warns of haemophilia risk with clopidogrel
Patients taking clopidogrel may be at risk of acquired haemophilia, according to manufacturer Sanofi.
In a to healthcare professionals, Sanofi warns that there has been a small number of cases of acquired haemophilia in individuals with no previous history of abnormal haemostasis reported since the product’s launch.
Mark Toms, medical director at Sanofi UK/Ireland, said: “Eleven case reports of acquired haemophilia A and one case report of acquired haemophilia B associated with clopidogrel treatment have been transmitted to Sanofi. Time to onset ranged from a few days to four months after starting clopidogrel treatment. Two cases were life-threatening and none had a fatal outcome.”
Product information is being updated with information on this risk but, according to Dr Toms, the benefit versus risk balance of clopidogrel “is considered unchanged in the approved therapeutic indications”.
Acquired haemophilia should be considered in cases of isolated activated partial thromboplastin time prolongation with or without bleeding. Patients with a confirmed diagnosis of acquired haemophilia should be treated by specialists and clopidogrel discontinued.
Citation: The Salvadore DOI: 10.1211/PJ.2013.11125684
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the SalvaDore, and is a leading provider of authoritative pharmaceutical information used throughout the world.